Human Microbiome Research and Development for Overcoming Pediatric Diseases
Launched by HANYANG UNIVERSITY · Feb 1, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how changes in the gut microbiome—the community of bacteria and other microorganisms in our digestive system—can affect children's health and development. Researchers want to understand how imbalances in these microorganisms might be linked to various pediatric diseases and how restoring a healthy gut microbiome can improve health outcomes over time. They are particularly interested in how the gut microbiome interacts with other parts of the body, like the lungs and brain.
The trial is open to children, including newborns, whose guardians provide consent. If your child participates, they will be involved in research that looks at their gut health and its connection to their overall well-being. The study is currently recruiting participants, and it aims to gather valuable information that could lead to new treatments for pediatric diseases in the future. Your child's participation could help improve understanding of how gut health impacts their growth and development.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • children (including newborns) who have obtained their consent from their guardians
- Exclusion Criteria:
- • subjects who did not obtain consent
About Hanyang University
Hanyang University is a prestigious educational and research institution located in South Korea, renowned for its commitment to advancing scientific knowledge and innovation. With a strong emphasis on interdisciplinary collaboration, the university conducts cutting-edge research across various fields, including medicine, engineering, and biotechnology. As a clinical trial sponsor, Hanyang University leverages its robust academic resources and expertise to facilitate the design, implementation, and management of clinical studies. The institution is dedicated to improving patient outcomes through rigorous research methodologies and ethical standards, contributing to the advancement of healthcare and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Hyun-Kyung Park, MD
Principal Investigator
Hanyang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported